The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Scottish Medicines Consortium Recommends Risankizumab; Plus Real-World Data on Secukinumab

Scottish Medicines Consortium Recommends Risankizumab; Plus Real-World Data on Secukinumab

November 4, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

SMC Recommends Risankizumab for Psoriasis
In October, the Scottish Medicines Consortium (SMC) published a positive, detailed advice document recommending risankizumab (Skyrizi) for treating adults with moderate to severe psoriasis.1 The treatment specifically for patients who are intolerant to conventional systemic therapies, such as cyclosporine, methotrexate and phototherapy, patients for whom conventional systemic therapies have failed or those who have a contraindication to these treatments.

You Might Also Like
  • Secukinumab: The Real World Experience of PsA Patients
  • Secukinumab Meets 5-Year Benchmark for Psoriasis
  • Risankizumab Promising for Psoriasis; Plus Canada Approves Brodalumab
Explore This Issue
December 2019
Also By This Author
  • FDA Approves Upadacitinib for RA

The detailed advice document was based on results of the phase 3 studies, UltIMMa-1, UltIMMa-2, IMMvent and IMMhance. Across all four of these studies, risankizumab showed high Psoriasis Area and Severity Index (PASI) 90 rates at Week 16, which were maintained through Week 52.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Real-World Data on Secukinumab
Secukinumab (Cosentyx) is a human IgG1κ monoclonal antibody that binds to the protein interleukin 17A and is approved to treat multiple diseases. Early this month, its manufacturer, Novartis, reported data on secukinumab from five real-world evidence and observational studies conducted in Europe, North America and Latin America. These studies provided a wide range of clinical insight for the treatment of more than 13,000 patients.2

The data from these studies show sustained efficacy, a favorable safety profile and improved quality of life for patients taking secukinumab for up to two-and-one-half years of use in the real world. Clinical evidence supports the use of secukinumab, which has demonstrated continued efficacy and safety for up to five years in patients with psoriasis, including for persistent psoriasis signs of the nails, scalp, palms and soles of the feet, psoriatic arthritis and ankylosing spondylitis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. AbbVie Inc. News release: AbbVie’s Skyrizi (risankizumab) accepted for use within NHS Scotland. 2019 Oct 7.
  2. Novartis. News release: Novartis real-world evidence confirms high efficacy, long-term response and favorable safety profile of Cosentyx in clinical practice. 2019 Oct 9.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Psoriasis, risankizumab, Scottish Medicines Consortium, secukinumabIssue: December 2019

You Might Also Like:
  • Secukinumab: The Real World Experience of PsA Patients
  • Secukinumab Meets 5-Year Benchmark for Psoriasis
  • Risankizumab Promising for Psoriasis; Plus Canada Approves Brodalumab
  • Secukinumab Receives 2 New Approvals: PsA & AS

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)